Asfotase alfa
Brand names: STRENSIQ
Therapeutic Indications
Asfotase alfa is indicated for:
Hypophosphatasia
Irrespective of gender only Children (1 year - 12 years old) , Adolescents (12 years - 18 years old) , Adults (18 - 65 years old)
Asfotase alfa is indicated for long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease.
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Subcutaneous - 2 mg/kg 3 times per week
Treatment 2: Subcutaneous - 1 mg/kg 6 times per week
Contraindications
Active ingredient Asfotase alfa is contraindicated in the following cases: